Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Assets: 2015-2024

Historic Assets for Cartesian Therapeutics (RNAC) over the last 10 years, with Dec 2024 value amounting to $435.0 million.

  • Cartesian Therapeutics' Assets fell 18.15% to $372.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $372.7 million, marking a year-over-year decrease of 18.15%. This contributed to the annual value of $435.0 million for FY2024, which is 42.61% up from last year.
  • According to the latest figures from FY2024, Cartesian Therapeutics' Assets is $435.0 million, which was up 42.61% from $305.1 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Assets ranged from a high of $435.0 million in FY2024 and a low of $159.9 million during FY2021.
  • Its 3-year average for Assets is $302.0 million, with a median of $305.1 million in 2023.
  • In the last 5 years, Cartesian Therapeutics' Assets fell by 3.36% in 2021 and then spiked by 83.89% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' Assets (Yearly) stood at $165.4 million in 2020, then decreased by 3.36% to $159.9 million in 2021, then increased by 3.75% to $165.9 million in 2022, then soared by 83.89% to $305.1 million in 2023, then skyrocketed by 42.61% to $435.0 million in 2024.